Elicera Therapeutics AB (8E8) Price & Analysis

0 Followers

8E8 Stock Chart & Stats

€0.47

€0.03(20.86%)

At close: Jan 08 4:00 PM EST

€0.47

€0.03(20.86%)

Day’s Range― - ―

52-Week Range€0.19 - €0.67

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€17.24M

Enterprise Value€123.71M

Total Cash (Recent Filing)€24.85M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.48

Next Earnings

Aug 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.41

Shares Outstanding66,736,374

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)10.19

Price to Sales (P/S)0.00

P/FCF Ratio-11.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.05

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetZero reported debt materially reduces financing cost risk and interest coverage pressure, giving management flexibility to time equity raises or partnerships. Over a 2–6 month horizon this durable leverage profile lowers insolvency risk and supports strategic R&D spending choices.

Focused Immuno-oncology R&DA clear strategic focus on CAR T and cell/gene therapies aligns with a multi-year structural growth area in oncology. Durable R&D specialization and a pipeline targeting hematologic and solid tumors supports long-term addressable market expansion and partnership/licensing opportunities.

Strong Gross Profit When Revenue ExistedHigh gross margins during revenue periods indicate favorable unit economics or high-margin collaboration/license revenue. If clinical programs translate to stable revenue streams, these margin dynamics can support scalable profitability once operating costs align with commercial revenues.

Bears Say

Persistent Cash BurnSustained negative operating and free cash flow is a durable constraint that forces reliance on external financing or partnerships. Ongoing cash burn increases dilution or negotiation pressure on deal terms, limiting strategic optionality and raising execution risk over the medium term.

Revenue Volatility And 2025 Zero RevenueLarge swings in revenue and a recent drop to zero signal weak commercial visibility and inconsistency converting R&D into sustainable sales. This structural revenue unpredictability complicates planning, partnership valuation, and makes multi-period forecasting and cash planning more difficult.

Declining Equity And Funding VulnerabilityMaterial equity erosion from cumulative losses reduces the balance-sheet buffer against shocks and limits borrowing capacity. This structural weakening increases the probability of dilutive capital raises and constrains strategic moves absent clear near-term revenue or partnership catalysts.

8E8 FAQ

What was Elicera Therapeutics AB’s price range in the past 12 months?

Elicera Therapeutics AB lowest stock price was €0.19 and its highest was €0.67 in the past 12 months.

What is Elicera Therapeutics AB’s market cap?

Elicera Therapeutics AB’s market cap is €17.24M.

When is Elicera Therapeutics AB’s upcoming earnings report date?

Elicera Therapeutics AB’s upcoming earnings report date is Aug 21, 2026 which is in 48 days.

How were Elicera Therapeutics AB’s earnings last quarter?

Elicera Therapeutics AB released its earnings results on Apr 21, 2026. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.009.

Is Elicera Therapeutics AB overvalued?

According to Wall Street analysts Elicera Therapeutics AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Elicera Therapeutics AB pay dividends?

Elicera Therapeutics AB does not currently pay dividends.

What is Elicera Therapeutics AB’s EPS estimate?

Elicera Therapeutics AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Elicera Therapeutics AB have?

Elicera Therapeutics AB has 66,736,374 shares outstanding.

What happened to Elicera Therapeutics AB’s price movement after its last earnings report?

Elicera Therapeutics AB reported an EPS of -€0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.677%.

Which hedge fund is a major shareholder of Elicera Therapeutics AB?

Currently, no hedge funds are holding shares in DE:8E8

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a Swedish immuno-oncology firm founded in Göteborg in 2014, is dedicated to the clinical development of cell and gene therapies that harness the immune system to combat cancer. Its promising pipeline features several drug candidates, including ELC-100, which is currently undergoing Phase I/II trials for neuroendocrine tumors. The company is also advancing ELC-201 and ELC-401 through preclinical development, with ELC-401 specifically targeting glioblastoma multiforme (a form of brain tumor). Furthermore, Elicera is developing ELC-301, a CAR T-cell therapy intended for the treatment of Non-Hodgkin's B-cell lymphoma. A cornerstone of their work is the iTANK technology platform, engineered to enhance the efficacy of their CAR T-cell therapies and stimulate killer T-cells to attack cancerous cells.